JP2025501913A5 - - Google Patents

Info

Publication number
JP2025501913A5
JP2025501913A5 JP2024538390A JP2024538390A JP2025501913A5 JP 2025501913 A5 JP2025501913 A5 JP 2025501913A5 JP 2024538390 A JP2024538390 A JP 2024538390A JP 2024538390 A JP2024538390 A JP 2024538390A JP 2025501913 A5 JP2025501913 A5 JP 2025501913A5
Authority
JP
Japan
Prior art keywords
seq
fusion protein
chain variable
variable region
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501913A (ja
Filing date
Publication date
Priority claimed from KR1020220001647A external-priority patent/KR20230105972A/ko
Application filed filed Critical
Publication of JP2025501913A publication Critical patent/JP2025501913A/ja
Publication of JP2025501913A5 publication Critical patent/JP2025501913A5/ja
Pending legal-status Critical Current

Links

JP2024538390A 2022-01-05 2022-12-27 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用 Pending JP2025501913A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020220001647A KR20230105972A (ko) 2022-01-05 2022-01-05 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
KR10-2022-0001647 2022-01-05
PCT/KR2022/021371 WO2023132547A1 (ko) 2022-01-05 2022-12-27 혈관신생 억제제가 결합된 항-c3b 항체 또는 항-c5 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
JP2025501913A JP2025501913A (ja) 2025-01-24
JP2025501913A5 true JP2025501913A5 (enExample) 2025-12-02

Family

ID=87073766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538390A Pending JP2025501913A (ja) 2022-01-05 2022-12-27 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用

Country Status (7)

Country Link
US (1) US20250074974A1 (enExample)
EP (1) EP4461745A4 (enExample)
JP (1) JP2025501913A (enExample)
KR (1) KR20230105972A (enExample)
CN (1) CN118510799A (enExample)
AU (1) AU2022430428A1 (enExample)
WO (1) WO2023132547A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022010273A1 (ko) * 2020-07-07 2022-01-13 주식회사 카나프테라퓨틱스 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4897690B2 (ja) 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
US20090220508A1 (en) * 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
RU2473563C2 (ru) * 2007-06-07 2013-01-27 Дженентек, Инк. АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
MA49279A (fr) * 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
WO2019112958A1 (en) 2017-12-05 2019-06-13 Abbvie Biotherapeutics Inc. Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
JP2022512657A (ja) * 2018-10-12 2022-02-07 トリカン・バイオテクノロジー・カンパニー・リミテッド 二機能性融合タンパク質およびその使用
US20250145673A1 (en) * 2021-03-18 2025-05-08 Affilogic Polypeptides for complement inhibition

Similar Documents

Publication Publication Date Title
US12398204B2 (en) Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist
JP2020114218A5 (enExample)
JP7107914B2 (ja) ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
BR112019022751A2 (pt) composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
CN109415435B (zh) 新型抗体形式
JP2023519213A5 (enExample)
JP2023130473A (ja) 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用
JP2023547662A (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
JP2025501913A5 (enExample)
US20250051460A1 (en) Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
JP2025525442A (ja) Ａｎｇ２／ｖｅｇｆ抗体およびその使用
CN114423788B (zh) 抗nrp1a抗体及其用于治疗眼或眼部疾病的用途
WO2024114641A1 (en) C5/vegf bispecific binding molecules
US20260055171A1 (en) Vegf antagonists and methods of use thereof
HK40126782A (zh) C5/vegf双特异性结合分子
RU2022102753A (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
RU2021125763A (ru) Биспецифическое антитело, специфически связывающееся с vegf и ang2
EA046884B1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение
EA043309B1 (ru) Биспецифические конструкции антител, вовлекающие т-клетки